Changes in circulating androgens during short term carbamazepine therapy.

Area of Science:

• Endocrinology
• Pharmacology
• Metabolism

Background:

• Carbamazepine (CBZ) is a widely used anticonvulsant.
• Chronic CBZ therapy is associated with sexual dysfunction in some patients.
• The underlying mechanisms of CBZ-induced sexual dysfunction are not fully understood.

Purpose of the Study:

• To investigate the effects of short-term carbamazepine (CBZ) administration on serum sex hormone concentrations in healthy males.
• To explore the potential relationship between CBZ-induced changes in hepatic enzyme activity and sex hormone metabolism.
• To elucidate potential mechanisms contributing to sexual dysfunction observed in patients on chronic anticonvulsant therapy.

Main Methods:

• Six healthy male subjects received carbamazepine (CBZ) 400 mg daily for 21 days.
• Serum concentrations of testosterone, androstenedione, dehydroepiandrosterone sulphate (DHAS), sex hormone binding globulin (SHBG), and luteinising hormone (LH) were measured.
• Hepatic microsomal enzyme activity was assessed by antipyrine clearance and CBZ concentration monitoring.

Main Results:

• CBZ administration induced hepatic microsomal enzyme activity, confirmed by increased antipyrine clearance and decreased CBZ levels.
• Within 7 days, SHBG levels increased, while testosterone, free testosterone fraction, DHAS, and androstenedione levels decreased significantly.
• By the end of the treatment, testosterone, free testosterone fraction, and androstenedione levels partially recovered, but DHAS remained low.

Conclusions:

• CBZ treatment leads to increased SHBG and enhanced androgen catabolism, likely due to induced hepatic monooxygenase activity.
• These hormonal alterations, particularly the decrease in androgens and increase in SHBG, may contribute to the sexual dysfunction reported in patients on chronic CBZ therapy.
• Further research is warranted to confirm these findings and explore therapeutic interventions.